| 生 娣,杨 娜,谢 谦,时雯婷,许 玲.罗氟司特对脓毒症炎症大鼠炎症因子及淋巴细胞的调控机制分析[J].现代生物医学进展英文版,2022,(14):2636-2641. |
| 罗氟司特对脓毒症炎症大鼠炎症因子及淋巴细胞的调控机制分析 |
| Regulatory Mechanism of Roflumilast on Inflammatory Factors and Lymphocytes in Septic Inflammatory Rats |
| Received:January 07, 2022 Revised:January 30, 2022 |
| DOI：10.13241/j.cnki.pmb.2022.14.007 |
| 中文关键词: 罗氟司特 JAK / STAT 脓毒症 miRNA-218 |
| 英文关键词: Roflumilast JAK / STAT Sepsis miRNA-218 |
| 基金项目:新疆维吾尔自治区自然科学基金项目（2017d01c166） |
|
| Hits: 697 |
| Download times: 402 |
| 中文摘要: |
| 摘要 目的：探究罗氟司特通过JAK/STAT途径对脓毒症炎症大鼠炎症因子及淋巴细胞的调控机制分析。方法：将54只SD大鼠随机分为正常组（n=18），模型组（n=18）和罗氟司特组（n=18），正常组正常喂养，模型组和罗氟司特组建立脓毒症大鼠模型。模型组和罗氟司特组腹膜内注射0.9 %的氯化钠和罗氟司特。干预7 d后，对大鼠取样。测定灌洗液中炎症细胞的数量、JAK和STAT-3的蛋白、AST和ALT、IL-6和TNF-α的mRNA表达。结果：在观察的7 d中，正常组大鼠均存活，生存率高于模型组和罗氟司特组（P<0.05），罗氟司特组生存率高于模型组（P<0.05）。与正常组相比，模型组和罗氟司特组术后症状评分均增加（P<0.05），罗氟司特组术后症状评分低于模型组（P<0.05）。模型组和罗氟司特组的miRNA-218表达低于正常组（P<0.05），而罗氟司特组高于模型组（P<0.05）；模型组和罗氟司特组淋巴细胞，中性粒细胞和单核细胞总数，JAK和STAT-3的蛋白质表达，AST、ALT、IL-6和TNF-α水平高于正常组（P<0.05），罗氟司特组上述指标低于模型组（P<0.05）。结论：罗氟司特通过JAK / STAT途径阻断miRNA-218表达，抑制促炎性细胞因子IL-6和TNF-α的表达，减轻脓毒症炎症的机制和肝脏损害并改善多发性脓毒症的生存率。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the regulation mechanism of roflumilast on inflammatory factors and lymphocytes in septic inflammatory rats through JAK/STAT pathway. Methods: 54 SD mice were randomly divided into normal group (n = 18), model group (n = 18) and roflumilast group (n=18). The normal group was fed normally, and the model group and roflumilast group were used to establish sepsis model. In the model group and roflumilast group, 0.9% sodium chloride and roflumilast were injected intraperitoneally. After 7 days of intervention, the mice were sampled. The number of inflammatory cells, Jak and Stat-3 protein, AST and alt, IL-6 and TNF-α mRNA expression were measured. Results: The survival rate of normal group was higher than that of model group and roflumilast group (P<0.05). The survival rate of roflumilast group was higher than that of model group (P<0.05). Compared with the normal group, the postoperative symptom scores of the model group and the roflumilast group were increased (P<0.05), and the postoperative symptom score of the roflumilast group was lower than that of the model group （P<0.05). The expression of mirna-218 in model group and roflumilast group was lower than that in normal group (P<0.05), while that in roflumilast group was higher than that in model group (P<0.05). The total number of lymphocytes, neutrophils and monocytes, the protein expression of JAK and Stat-3, the levels of AST, alt, IL-6 and TNF-α in model group and roflumilast group were higher than those in normal group (P<0.05). The above indexes in roflumilast group were lower than those in model group (P<0.05). Conclusion: Roflumilast blocks the expression of miRNA-218 through the JAK/STAT pathway, inhibits the expression of pro-inflammatory cytokines IL-6 and TNF-α, reduces the mechanism of sepsis inflammation and liver damage, and improves the development of multiple sepsis survival rate. |
|
View Full Text
View/Add Comment Download reader |
| Close |
